Summarized by Masters of Longevity from Fight Aging!.
An SUV39H1-targeting inhibitor lowered H3K9me3 and improved pathology in mice.
Key Takeaways
- H3K9me3 was increased early across the AD continuum.
- ETP69 treatment showed reduced cerebral H3K9me3 in mice.
- Behavioral improvements were reported but causality remains unproven.
